CDC Advisory Committee on Immunization Practices Recommends HibMenCY for Infants at Increased Risk for Meningococcal Disease

The Advisory Committee for Immunization Practices voted today 13 to 1, with 1 abstention, to recommend that infants at increased risk for meningococcal disease should be vaccinated with 4 doses of HibMenCY at 2, 4, 6, and 12 through 15 months. These include infants with recognized persistent complement pathway deficiencies and infants who have anatomic or functional asplenia including sickle cell disease. HibMenCY can be used in infants ages 2 through 18 months who are in communities with serogroup C and Y meningococcal disease outbreaks.

This Coalition transmission preserves metadata, trust context, and source routing for a Public Intelligence item from CDC. The complete article remains with the original publisher.

Content handling is marked as Public Domain. Use the source article link for the full report, updates, corrections, and publisher-controlled context.